Oric Pharmaceuticals Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
All right. Hello, and welcome. My name is Michael Schmidt. I'm a Biotech Analyst with Guggenheim, and it's my great pleasure to welcome the ORIC team. With us today, we have Jacob Chacko, CEO; as well as Dominic Piscitelli, Chief Financial Officer. Welcome, guys. Thanks for joining us.
Thanks for having us, Michael.
Questions & Answers
Yes. So Jacob, ORIC has a diverse portfolio of oncology drugs and then an interesting history, I think. Just remind us of the overall business model, and guiding principles of each strategy?
Sure thing, Michael. As you mentioned, I think we have one of the most robust pipelines of oncology therapeutics in small-cap biotech today. There's a couple things that I think makes us unique. One is that we've got the full slate of internal
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

